A large diversified pharmaceutical firm wished to evaluate the risks and rewards of a potential large drug-licensing deal. The complicating factor was that the proposed M&A contract allowed either of the two parties involved to change the business terms, after the deal would be signed (i.e. ‘flip’ the terms).
EpiX Analytics provided strategic advice and constructed a Monte Carlo simulation model that captured the medical and financial risks of the drugs as well as the “optionality” within the potential M&A deal-terms.
The results of the model allowed the client to take a more favorable negotiation strategy which resulted in a successful licensing deal.